U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Strong Fertility Center - 593262 - 12/11/2020
  1. Warning Letters

CLOSEOUT LETTER

Strong Fertility Center MARCS-CMS 593262 —

Delivery Method:
VIA UNITED PARCEL SERVICE
Reference #:
OBPO 20-593262
Product:
Biologics

Recipient:
Recipient Name
Kathleen Hoeger, MD
Recipient Title
Director of Tissue Bank Operations
Strong Fertility Center

500 Red Creek Drive
Suite 220
Rochester, NY 14623-4285
United States

Issuing Office:
Office of Biological Products Operations – Division I

United States


Dear Dr. Hoeger:

The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter #OBPO 20-593262 dated October 29, 2019. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Elizabeth Waltrip
Program Division Director

Back to Top